What goes up must come down (at least a little bit).

Stocks ran up A LOT during covid, it couldn't continue forever and it didn't.

People who felt rich because they made a ton of paper profits on the stock market now feel poorer because they have paper losses in the stock market.

That and inflation of course is really taking money out of peoples pockets.

Real world things that effect the way people act have occurred.

Yep, I feel it. I was about to impulse buy a deck, and then after looking at the market decided not to. I'm not alone in tightening spend.

this is those kinds of mob behaviours that induce crisises, the self-fulfilling cause of a crash of consumption that will then actually make you need to tighten spending. The first initiators are the most responsible.

It's cause and effect. You can't convince people not to worry about things they're worried about.

Well if you actually convince them you solve the crisis. Since this mindset is not taught in public education it is left as an individual responsibility. I would promote autocratic censorship/tamming down of hysteric/fear mongering mediatic reporting on this specific topic but our government are not ready for that.

It might be the case that I just haven't communicated my point clearly enough. To a surprising extent, "self-fulfilling prophety that is auto-amplified in mediatic echo chambers and by feedback mechanism on X, Y and Z" describes a large portion of the human social condition.

I think it's clear from the pandemic that stock values do not correlate with the economy.

They do correlate with the economy, they just don't correlate solely with the economy.

off-topic: Since you made idealmedtech, you should be interested in publicising the effect of ALCAR on glycemia/insulin. Since it nudge the mitochondria to increase the ratio of lipids/fatty acid consumption and reduce the consumption of glucose, it is very positive for the protection of both kinds of diabetes, in a side effect free manner. The number of lives/quality of life that could be saved if this information was more widespread is astonishing, especially since your website help to measure the impact.

We're not really in the business of drugs/supplements, so unfortunately I can't comment on the efficacy of ALCAR and other drugs on the treatment of diabetes. If you have any papers on the topic, feel free to email me (linked on my profile) and I would be happy to discuss when there's time!

Also, as much as I wish we had any sort of platform through idealmedtech.com, our traffic is quite low, mostly from investors and people pitching SaaS products

well take a look at this for example https://pubmed.ncbi.nlm.nih.gov/19620516/

That's fascinating! Insulin sensitivity is an incredibly complex mechanism, and is always in flux. Hyperinsulemic clamps are one way to measure the boundaries of insulin sensitivity, but doesn't really help you understand the day to day individual dynamics very well. Like I said, drugs are _not_ our area of expertise, so I can't comment much more than that.

State of the art treatment these days (at least in artificial pancreas land, where I spend all of my time) is more focused on sensitivity-agnostic treatment; figuring out the insulin sensitivity dynamically rather than trying to control the sensitivity itself (it's much more multifaceted than a few hormones, we're talking hundreds of possible ways it can change).

Also, and I'm sure the authors would acknowledge this, n=32 is enough to demonstrate a possible effect, but not nearly enough to show this effect in the population at large. You usually need n~5000 or more for such effects to be shown generally, though the actual number depends a lot on the drug and what you're trying to treat.

We're conducting our first human study at a world renowned US diabetes center soon, I'll see what our PI thinks of this work. Thanks for sharing.